Evidence map›Paper›PMID 31615920›Full record

ArticleLife science alliance2019

Drug-induced chromatin accessibility changes associate with sensitivity to liver tumor promotion.

Antonio Vitobello, Juliane Perner, Johanna Beil, Jiang Zhu, Alberto Del Río-Espínola, Laurent Morawiec, Magdalena Westphal, Valérie Dubost, Marc Altorfer, Ulrike Naumann and 8 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Life science alliance, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Impact of Neonatal Activation of Nuclear Receptor CAR (Nr1i3) on Cyp2 Gene Expression in Adult Mouse Liver.Toxicological sciences : an official journal of the Society of Toxicology · 2022
    Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 3 institutions in 5 countries.

Antonio VitobelloNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.ORCID 0000-0003-3717-8374
Juliane PernerNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Johanna BeilNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Jiang ZhuNIBR, Cambridge, MA, USA.
Alberto Del Río-EspínolaNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Laurent MorawiecNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Magdalena WestphalNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Valérie DubostNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Marc AltorferNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Ulrike NaumannNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Arne MuellerNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Karen KapurNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Mark BorowskyNIBR, Cambridge, MA, USA.
Colin HendersonSchool of Medicine, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.ORCID 0000-0002-4764-639X
C Roland WolfSchool of Medicine, Jacqui Wood Cancer Centre, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
Michael SchwarzDepartment of Toxicology, University of Tübingen, Tübingen, Germany.
Jonathan MoggsNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland.
Rémi TerranovaNovartis Institutes for BioMedical Research (NIBR), Basel, Switzerland remi.terranova@novartis.com.ORCID 0000-0002-2119-679X
Novartis (Switzerland) · CHUniversity of Dundee · GBInnovative Medicines Initiative · BE

Funding

Cancer Research UK 10822Cancer Research UK 15709Cancer Research UK 22357Cancer Research UK C4639/A10822
6 · The paper itself

Abstract

Liver cancer susceptibility varies amongst humans and between experimental animal models because of multiple genetic and epigenetic factors. The molecular characterization of such susceptibilities has the potential to enhance cancer risk assessment of xenobiotic exposures and disease prevention strategies. Here, using DNase I hypersensitivity mapping coupled with transcriptomic profiling, we investigate perturbations in

Indexed as

AnimalsChromatinChromatin Assembly and DisassemblyComputational BiologyEpigenesis, GeneticGene Expression ProfilingGene Regulatory NetworksHumansLiver NeoplasmsMaleMicePhenobarbitalWnt Signaling PathwayChromatinPhenobarbital

Identifiers

PMID31615920
PMCPMC6795216
OpenAlexW2980960166

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.